214 results on '"Kamato, Danielle"'
Search Results
2. Response to retention hypothesis as a source of targets for arterial wall-directed therapies to prevent atherosclerosis: A critical review
3. Mechanistic insight: Linking cardiovascular complications of inflammatory bowel disease
4. Lipid: Extracellular Matrix Interactions as Therapeutic Targets in the Atherosclerosis of Diabetes
5. Moscatilin inhibits vascular calcification by activating IL13RA2-dependent inhibition of STAT3 and attenuating the WNT3/β-catenin signalling pathway
6. Endothelin-1 mediated glycosaminoglycan synthesizing gene expression involves NOX-dependent transactivation of the transforming growth factor-β receptor
7. PAR2 activation on human tubular epithelial cells engages converging signaling pathways to induce an inflammatory and fibrotic milieu.
8. Lipopolysaccharide acting via toll-like receptor 4 transactivates the TGF-β receptor in vascular smooth muscle cells
9. Smad2 linker region phosphorylation is an autonomous cell signalling pathway: Implications for multiple disease pathologies
10. Smad linker region phosphorylation is a signalling pathway in its own right and not only a modulator of canonical TGF-β signalling
11. Mechanisms of PAR-1 mediated kinase receptor transactivation: Smad linker region phosphorylation
12. Targeted Molecular Imaging of Cardiovascular Diseases by Iron Oxide Nanoparticles
13. G protein coupled receptors can transduce signals through carboxy terminal and linker region phosphorylation of Smad transcription factors
14. Transforming growth factor–β1 mediated CHST11 and CHSY1 mRNA expression is ROS dependent in vascular smooth muscle cells
15. Mechanistic insight: Linking cardiovascular complications of inflammatory bowel disease
16. Gαq Is the Specific Mediator of PAR-1 Transactivation of Kinase Receptors in Vascular Smooth Muscle Cells
17. Mouse models of atherosclerosis in translational research
18. Non-Mouse Models of Atherosclerosis: Approaches to Exploring the Translational Potential of New Therapies
19. Insights into cellular signalling by G protein coupled receptor transactivation of cell surface protein kinase receptors
20. Gaq proteins: molecular pharmacology and therapeutic potential
21. 25 Years of endothelin research: the next generation
22. Akt acts as a switch for GPCR transactivation of the TGF‐β receptor type 1
23. Evaluation of the potential synergism of imatinib-related poly kinase inhibitors using growth factor stimulated proteoglycan synthesis as a model response
24. Lipopolysaccharide Acting Via Toll Like Receptor 4 Transactivates The TGF-β Receptor in Vascular Smooth Muscle cells
25. YY‐11, a camel milk‐derived peptide, inhibits TGF‐β‐mediated atherogenic signaling in human vascular smooth muscle cells
26. Peptidyl-prolyl isomerases: Functionality and potential therapeutic targets in cardiovascular disease
27. Endothelin‐1 dependent expression of GAG genes involves NOX and p38 mediated Smad linker region phosphorylation.
28. Transforming growth factor β-mediated site-specific Smad linker region phosphorylation in vascular endothelial cells
29. Endothelial Dysfunction and Cardiovascular Disease: History and Analysis of the Clinical Utility of the Relationship
30. Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies
31. Curcumin Inhibits Lysophosphatidic Acid Mediated MCP-1 Expression via Blocking ROCK Signalling
32. Akt acts as a switch for GPCR transactivation of the TGF‐β receptor type 1.
33. Targeted Molecular Imaging of Cardiovascular Diseases by Iron Oxide Nanoparticles
34. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
35. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
36. Lysophosphatidic acid receptor 5 transactivation of TGFBR1 stimulates the mRNA expression of proteoglycan synthesizing genes XYLT1 and CHST3
37. Artemisinin inhibits glycosaminoglycan chain synthesizing gene expression but not proliferation of human vascular smooth muscle cells
38. Suramin inhibits PDGF-stimulated receptor phosphorylation, proteoglycan synthesis and glycosaminoglycan hyperelongation in human vascular smooth muscle cells
39. (S)-[6]-Gingerol inhibits TGF-β-stimulated biglycan synthesis but not glycosaminoglycan hyperelongation in human vascular smooth muscle cells
40. Therapeutic implications of endothelin and thrombin G-protein-coupled receptor transactivation of tyrosine and serine/threonine kinase cell surface receptors
41. YY‐11, a camel milk‐derived peptide, inhibits TGF‐β‐mediated atherogenic signaling in human vascular smooth muscle cells.
42. Cell biology of Smad2/3 linker region phosphorylation in vascular smooth muscle
43. Toll-like Receptor 4 Stimulates Gene Expression via Smad2 Linker Region Phosphorylation in Vascular Smooth Muscle Cells
44. The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease
45. ROS directly activates transforming growth factor β type 1 receptor signalling in human vascular smooth muscle cells
46. Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease
47. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential.
48. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
49. GPCR transactivation signalling in vascular smooth muscle cells: role of NADPH oxidases and reactive oxygen species
50. Smad linker region phosphorylation is a signalling pathway in its own right and not only a modulator of canonical TGF-β signalling
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.